Short term outcome following acute phase switch among P2Y
Acute coronary syndrome
Clopidogrel
Novel P2Y12 inhibitors
Prasugrel
Switching
Ticagrelor
Journal
International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
06
09
2018
revised:
17
11
2018
accepted:
19
11
2018
entrez:
19
12
2018
pubmed:
19
12
2018
medline:
19
12
2018
Statut:
epublish
Résumé
The efficacy and safety of switching P2Y MEDLINE/PubMed/SCOPUS/Cochrane databases were screened for studies regarding switching of P2Y 22,500 patients from 14 studies were included. Unstable angina/non-ST elevation myocardial infarction (62.0%, interquartile range, 52.8%-68.0%) was the most common clinical presentation. The total number switched was 4294 (19.1%); escalation in 3416 (79.5%) patients (from clopidogrel to prasugrel, 62.9%) and de-escalation in 18.5%. Pooled analysis revealed no significant differences in MACE for any comparison; risk of bleeding was significantly increased among switched patients overall (odds ratio [OR], 1.60; 95% confidence interval [CI] 1.22-2.10) and increased in the escalation group (OR, 1.51; 95% CI, 1.06-2.16). Among patients presenting with ACS, switching from one P2Y
Identifiants
pubmed: 30560202
doi: 10.1016/j.ijcha.2018.11.008
pii: S2352-9067(18)30127-1
pmc: PMC6288462
doi:
Types de publication
Journal Article
Langues
eng
Pagination
39-45Commentaires et corrections
Type : ErratumIn
Références
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
N Engl J Med. 2007 Nov 15;357(20):2001-15
pubmed: 17982182
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
J Am Coll Cardiol. 2010 Sep 21;56(13):1017-23
pubmed: 20846599
Am J Cardiol. 2013 Mar 15;111(6):841-5
pubmed: 23273719
JACC Cardiovasc Interv. 2013 Feb;6(2):158-65
pubmed: 23428007
Circ Cardiovasc Interv. 2013 Oct 1;6(5):567-74
pubmed: 24065443
Am Heart J. 2014 Jan;167(1):68-76.e2
pubmed: 24332144
J Thromb Thrombolysis. 2014 Oct;38(3):388-94
pubmed: 24659130
J Interv Cardiol. 2014 Aug;27(4):365-72
pubmed: 25041356
Eur Heart J Acute Cardiovasc Care. 2015 Jun;4(3):220-9
pubmed: 25182465
J Thromb Thrombolysis. 2015 May;39(4):499-507
pubmed: 25274415
Eur Heart J Acute Cardiovasc Care. 2015 Oct;4(5):441-52
pubmed: 25414322
Eur Heart J Acute Cardiovasc Care. 2015 Dec;4(6):499-508
pubmed: 25515725
Nat Rev Cardiol. 2016 Jan;13(1):11-27
pubmed: 26283269
Eur J Clin Pharmacol. 2016 Jan;72(1):83-91
pubmed: 26453463
J Cardiovasc Pharmacol. 2016 Apr;67(4):336-43
pubmed: 26771153
Platelets. 2016 Jul;27(5):484-7
pubmed: 27050796
Am Heart J. 2016 Jun;176:44-52
pubmed: 27264219
Int J Cardiol. 2017 Feb 1;228:459-464
pubmed: 27870977
EuroIntervention. 2017 Jul 20;13(4):459-466
pubmed: 28374678
Eur Heart J. 2017 Nov 1;38(41):3070-3078
pubmed: 28510646
Lancet. 2017 Oct 14;390(10104):1747-1757
pubmed: 28855078
Eur Heart J. 2018 Jan 14;39(3):213-260
pubmed: 28886622
Eur Heart J. 2017 Nov 7;38(42):3160-3172
pubmed: 29020300
Circulation. 2017 Nov 14;136(20):1955-1975
pubmed: 29084738